Systemic lupus erythematosus (SLE) is an autoimmune disease that produces large amounts of immune complexes and autoantibodies and causes damage to the kidneys, skin, joints, and central nervous system. Current SLE treatment is mostly glucocorticoid-led drug therapy, which has more toxic side effects...
For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for
56 The prognosis of PML is poor. Notwithstanding that mortality has substantially dropped since the introduction of highly active antiretroviral therapy (HAART) for treatment of AIDS, survival of patients with PML 1 year after diagnosis ranges only from 38% to 62%.34 No pathognomonic initial ...
However, most patients with WM will become symptomatic during the course of the disease, due to anemia, hyperviscosity, neuropathy, or other processes, necessitating therapy. Current treatment options for symptomatic WM patients include alkylating agents, proteasome inhibitors and anti-CD20 monoclonal ...
cessation [102]. In this context, the CJM112 trial might have been an important step towards a more personalized selective treatment approach in MS, i.e., identification of those patients whose MS disease is especially IL-17 driven and initiation of a specific anti-IL-17 therapy with CJM1...
[5]The treatment that has many of my patients curious and excited—CART-19 therapy—will be presented in a study of patients with acute lymphoblastic leukemia of the B-cell variety.[6]We will see data from a triplet of biologic agents—ublituximab (another anti-CD20 agent), TGR1202 (a...
In this review, we discuss the biology of CD123 and prior attempts to target this cell surface marker as part of anti-leukemic therapy. We then summarize and discuss the five CD123-directed bispecific antibodies currently in clinical trials for treatment of AML and provide practical insights ...
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb m... DG Maloney,...
The emergence of new novel therapeutic agents which directly target molecules that are uniquely or abnormally expressed in cancer cells (molecular targeted therapy, MTT) has changed dramatically the treatment of cancer in recent years. The clinical benefit associated with these agents is typically limite...
Management of PTLD depends on the type of the disease. Polyclonal disease is treated by lowering of immunosuppression and introduction of antiviral drugs [127–129]. Treatment of monoclonal disease includes lowering immunosuppression along with use of antiCD20 antibody (Rituzimab) as the first step....